Alessandro Parisi, Riccardo Giampieri, Alex Mammarella, Cristiano Felicetti, Lisa Salvatore, Maria Bensi, Maria Grazia Maratta, Antonia Strippoli, Roberto Filippi, Maria Antonietta Satolli, Angelica Petrillo, Bruno Daniele, Michele De Tursi, Pietro Di Marino, Guido Giordano, Matteo Landriscina, Pasquale Vitale, Ina Valeria Zurlo, Emanuela Dell'Aquila, Silverio Tomao, Ilaria Depetris, Francesca Romana Di Pietro, Federica Zoratto, Davide Ciardiello, Maria Vittoria Pensieri, Ornella Garrone, Barbara Galassi, Claudio Ferri, Rossana Berardi, Michele Ghidini
Aim: The aim of the current study is to investigate the impact of primary compared to secondary chemotherapy-induced nausea and vomiting (CINV) prophylaxis with NK1 receptor antagonists (NK1-RA) in patients affected by gastrointestinal malignancies and treated with oxaliplatin- and/or irinotecan-based doublet or triplet regimens. Study design and methods: Clinical data of patients affected by gastrointestinal malignancies, treated with an oxaliplatin and/or irinotecan-based doublet or triplet regimen as neo/adjuvant or advanced-line treatment, and who received NK1-RA as primary (from the first cycle of treatment) or secondary (after the onset of CINV with a previous regimen with 5HT3-RA and dexamethasone) prophylaxis for CINV, were retrospectively collected in an observational study involving 16 Italian centers...
2022: Frontiers in Oncology